Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 43

Sort by

Sort Order Select

Journal Articles

Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study

Blood (2024) 144 (18): 1924–1935.

https://doi.org/10.1182/blood.2024024631

Published: 2024

Includes: Supplemental data

Journal Articles

The Impact of Fitness and Dose Intensity on Safety and Efficacy Outcomes after Venetoclax-Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia

Blood (2023) 142 (Supplement 1): 4639.

https://doi.org/10.1182/blood-2023-188827

Published: 2023

Journal Articles

Pharmacogenetic Study of Ibrutinib Toxicity in Chronic Lymphocytic Leukemia Patients

Jorge Labrador, Maria Victoria Cuevas, Cristina Alonso-Madrigal, Pablo Zubiaur, Raul Azibeiro, Beatriz Cuevas, Rodolfo Alvarez, Francisco Javier Diaz-Galvez, Tomas Jose Gonzalez-Lopez, Raquel Alcaraz, Gina Paola Mejía-Abril, Javier Loscertales, Francisco Abad, Miriam Saiz-Rodríguez

Blood (2022) 140 (Supplement 1): 12405–12406.

https://doi.org/10.1182/blood-2022-163176

Published: 2022

Journal Articles

Efficacy and Safety of Treatment Venetoclax Monotherapy or Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) in the Real-World Setting in Spain: An Update of the Venares Study

Blood (2022) 140 (Supplement 1): 9908–9910.

https://doi.org/10.1182/blood-2022-162186

Published: 2022

Journal Articles

Long-Term Follow-up of Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia: A Single-Center Experience

Cristina García Herce, Valle Gómez García de Soria, Alejandro Alonso, Samantha Feijóo, Ana García-Noblejas, Javier Loscertales, Angela Figuera, Juan Luis Steegmann

Blood (2022) 140 (Supplement 1): 12215–12216.

https://doi.org/10.1182/blood-2022-159800

Published: 2022

Journal Articles

Interobserver Variability with the Diagnosis of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) ¿Is the Threshold of 20% Bone Marrow Blasts Reproducible?

Blood (2021) 138 (Supplement 1): 2607.

https://doi.org/10.1182/blood-2021-149147

Published: 2021

Journal Articles

Efficacy and Safety of Treatment Venetoclax Monotherapy or Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) in the Real -World Setting in Spain: The Venares Study

Blood (2021) 138 (Supplement 1): 1561.

https://doi.org/10.1182/blood-2021-147685

Published: 2021

Journal Articles

Single-Agent Ibrutinib As First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL) in Routine Clinical Practice in Spain

Pau Abrisqueta Costa, Javier Loscertales, MD, Maria Jose Terol, Angel Ramirez Payer, Macarena Ortiz Pareja, Inmaculada Perez, Carolina Cuellar, Margarita Fernandez De La Mata, Alicia Rodriguez, MD, Ana Lario, Julio Delgado, MD, Ana Cristina Godoy, PhD, Jose M Arguiñano, Maria José Berruezo, Ana C Oliveira, MD PhD, Jose Angel Hernandez-Rivas, MD PhD, María-Dolores García-Malo, MD, Angeles Medina, MD, Paloma García Martín, Santiago Osorio-Prendes, MD, Patricia Baltasar, Miguel Fernandez, MD, Fernando Marco, María-Jesús Vidal, Alicia Susana Smucler Simonovich, Montserrat Lopez Rubio, PhD, Isidro Jarque, Alexia Suárez Cabrera, Ruben Fernandez, MD, Aima Lancharro Anchel, Eduardo Rios Herranz, Carmen Losada, Ernesto Pérez Persona, Ricardo Francisco Garcia, Dr., Rafael Ramos, Lucrecia Yáñez, MD PhD, Jose Luis Bello, MD, Cristina Loriente, Miguel Villanueva

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-136036

Published: 2020

Journal Articles

Front-Line Treatment with Obinutuzumab ± Chlorambucil for Chronic Lymphocytic Leukemia in Real-World Clinical Practice: Results of a Multinational, Multicenter Study By Eric and Icllsg

Yair Herishanu, MD, Adir Shaulov, MD, Riva Fineman, MD, Sandra Bašić-Kinda, MD, Ariel Aviv, MD, Ewa Wasik-Szczepanek, MD PhD, Ozren Jaksic, MD PhD, Mihnea Zdrenghea, MD, Uri Greenbaum, MD, Inga Mandac, MD, Martin Simkovic, MD PhD, Marta Morawska, MD, Ohad Benjamini, MD, Martin Spacek, MD, Anatoly Nemets, MD, Osnat Bairey, MD PhD, Andrea Visentin, MD, Rosa Ruchlemer, MD, Luca Laurenti, MD, Oana Stanca Ciocan, MD, Michael Doubek, MD PhD, Lev Shvidel, MD, Nagib Deli, MD, Fatima Miras Calvo, MD, Anne De Meûter, Maria Dimou, MD PhD, Francesca Romana Mauro, MD, Marta Coscia, MD PhD, Horia Bumbea, MD PhD, Szász Róbert, Tamar Tadmor, MD, Odit Gutwein, Massimo Gentile, Lydia Scarfo, MD, Alessandra Tedeschi, MD, Paolo Sportoletti, Eva Gimeno Vázquez, Juan Marquet Palomanes, MD, Sarit Assouline, MD, Maria Papaioannou, Andrei Breaster, MD, Luciano Levato, MD, Michael Gregor, MD, Gian Matteo Rigolin, MD, Javier Loscertales, MD, Angeles Medina Perez, MD, Marten R. Nijziel, MD PhD, Viola Maria Popov, MDPhDMSc, Rosa Collado, MD, Irma Slavutsky, Shai Levi, MSc, Aaron Polliack, MD, Paolo Ghia, MD PhD

Blood (2019) 134 (Supplement_1): 1766.

https://doi.org/10.1182/blood-2019-122309

Published: 2019

Journal Articles

Retrospective Non-Interventional Assessment of the Use of Idelalisib in Relapsed/Refractory Chronic Lymphocytic Leukemia Patients in Spain

Blood (2019) 134 (Supplement_1): 5473.

https://doi.org/10.1182/blood-2019-126588

Published: 2019

Journal Articles

Long-Term Evaluation of Efficacy and Safety of Ofatumumab Added to Fludarabine & Cyclophosphamide in Subjects with Relapsed Chronic Lymphocytic Leukemia: Final Analysis of Complement 2 Trial

Sebastian Grosicki, MD PhD, Ewa Lech-Maranda, MD PhD, K Govind Babu, MD DM, Justyna Rybka, MD PhD, Elena Litvinskaya, PhD, Javier Loscertales, MD, Irina Kryachok, Prof., PhD, Janusz Kłoczko, Prof., PhD, Grygoriy Rekhtman, MD, Wojciech Homenda, MD PhD, Jerzy Blonski, MD PhD, Tommaso Stefanelli, Ghislaine Vincent, Hiya Banerjee, Tadeusz Robak, MD PhD

Blood (2018) 132 (Supplement 1): 3151.

https://doi.org/10.1182/blood-2018-99-112139

Published: 2018

Journal Articles

Clinical Outcome and Prognostic Factors of Patients with Richter's Syndrome: Retrospective Multicenter Study of the Spanish Chronic Lymphocytic Leukemia (CLL) Study Group (GELLC)

Pau Abrisqueta, MD PhD, Julio Delgado, MD, Miguel Alcoceba, PhD, Marcos González, MD, Ana C Oliveira, MD PhD, Javier Loscertales, MD, Jose Angel Hernandez-Rivas, Christelle Ferra, Raul Cordoba, MD PhD, Lucrecia Yañez, MD, Angeles Medina, MD, Cristina Motllo, Anna Varela, Francesc Bosch

Blood (2017) 130 (Supplement 1): 2995.

https://doi.org/10.1182/blood.V130.Suppl_1.2995.2995

Published: 2017

Journal Articles

Updated Analysis of Overall Survival in Randomized Phase III Study of Idelalisib in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL

Andrew D. Zelenetz, Jennifer R. Brown, Julio Delgado, Herbert Eradat, Paolo Ghia, Abraham Jacob, Wojciech Jurczak, Javier Loscertales, Donald MacDonald, Franck Morschhauser, Javier De la Serna, Mazyar Shadman, Christopher Pocock, Adeboye Henry Adewoye, Yeonhee Kim, David Simpson, Stephan Stilgenbauer

Blood (2016) 128 (22): 231.

https://doi.org/10.1182/blood.V128.22.231.231

Published: 2016

Journal Articles

Dynamics of Hemorragic Events and Primary Hemostasis Deffects during Treatment with Ibrutinib. Real-Life Experience

Natalia Acedo, Javier Loscertales, Beatriz Aguado, MD, Yizel Paz, Elena Jimenez-Barral, Alvaro Arriero, Adrian Alegre

Blood (2016) 128 (22): 4936.

https://doi.org/10.1182/blood.V128.22.4936.4936

Published: 2016

Journal Articles

Early Changes in Circulating T-Cell Immune Profiles in Patients with Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Data from the Phase 3, Double-Blind HELIOS Trial

Rajendra Damle, PhD, Michael Schaffer, PhD, Shalini Chaturvedi, PhD, Charles Phelps, MSc, Regina Aquino, MSc, Michelle Mahler, MD, Mariya Salman, PhD, Angela Howes, PhD, Javier Loscertales, MD PhD, Marek Trneny, MD, Dina Ben Yehuda, MD, Alexander Pristupa, MD, Asher A. Chanan-Khan, MD, Sriram Balasubramanian, PhD

Blood (2016) 128 (22): 4397.

https://doi.org/10.1182/blood.V128.22.4397.4397

Published: 2016

Journal Articles

Systemic Exposure of Rituximab Increased By Ibrutinib: Pharmacokinetic Results from the Helios Trial

Blood (2016) 128 (22): 4403.

https://doi.org/10.1182/blood.V128.22.4403.4403

Published: 2016

Journal Articles

Improvement of Quality of Response with Ibrutinib Plus Bendamustine/Rituximab Vs Placebo Plus Bendamustine/Rituximab for Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Blood (2015) 126 (23): 2938.

https://doi.org/10.1182/blood.V126.23.2938.2938

Published: 2015

Journal Articles

Insights into the Management of Adverse Events in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Experience from the Phase 3 HELIOS Study of Ibrutinib Combined with Bendamustine/Rituximab

Blood (2015) 126 (23): 2936.

https://doi.org/10.1182/blood.V126.23.2936.2936

Published: 2015

Journal Articles

Health-Related Quality of Life and Patient-Reported Outcomes in Patients Receiving Ofatumumab in Combination with Fludarabine and Cyclophosphamide (FC) Versus FC Alone in the Complement 2 Trial

Tadeusz Robak, MD Professor, Krzysztof Warzocha, MD PhD, K Govind Babu, Yaroslav Kulyaba, Kazimierz Kuliczkowski, Kudrat Abdulkadyrov, MD PhD, Javier Loscertales, Iryna Kryachok, Janusz Kloczko, Grygoriy Rekhtman, Wojciech Homenda, Jerzy Blonski, Astrid McKeown, PhD, Chai-Ni Chang, Stephanie C Manson, Steen Lisby, Ira V. Gupta, MD, Sebastian Grosicki, MD PhD

Blood (2015) 126 (23): 5288.

https://doi.org/10.1182/blood.V126.23.5288.5288

Published: 2015

Journal Articles

Development of a High-Throughput Screening Assay with Nurse-like Cell-Based Microenviroment in Chronic Lymphoid Leukemia Cells.

Blood (2014) 124 (21): 3639.

https://doi.org/10.1182/blood.V124.21.3639.3639

Published: 2014

NARROW

Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study

The Impact of Fitness and Dose Intensity on Safety and Efficacy Outcomes after Venetoclax-Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia

Pharmacogenetic Study of Ibrutinib Toxicity in Chronic Lymphocytic Leukemia Patients

Efficacy and Safety of Treatment Venetoclax Monotherapy or Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) in the Real-World Setting in Spain: An Update of the Venares Study

Long-Term Follow-up of Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia: A Single-Center Experience

Interobserver Variability with the Diagnosis of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) ¿Is the Threshold of 20% Bone Marrow Blasts Reproducible?

Efficacy and Safety of Treatment Venetoclax Monotherapy or Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) in the Real -World Setting in Spain: The Venares Study

Single-Agent Ibrutinib As First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL) in Routine Clinical Practice in Spain

Front-Line Treatment with Obinutuzumab ± Chlorambucil for Chronic Lymphocytic Leukemia in Real-World Clinical Practice: Results of a Multinational, Multicenter Study By Eric and Icllsg

Retrospective Non-Interventional Assessment of the Use of Idelalisib in Relapsed/Refractory Chronic Lymphocytic Leukemia Patients in Spain

Long-Term Evaluation of Efficacy and Safety of Ofatumumab Added to Fludarabine & Cyclophosphamide in Subjects with Relapsed Chronic Lymphocytic Leukemia: Final Analysis of Complement 2 Trial

Clinical Outcome and Prognostic Factors of Patients with Richter's Syndrome: Retrospective Multicenter Study of the Spanish Chronic Lymphocytic Leukemia (CLL) Study Group (GELLC)

Updated Analysis of Overall Survival in Randomized Phase III Study of Idelalisib in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL

Dynamics of Hemorragic Events and Primary Hemostasis Deffects during Treatment with Ibrutinib. Real-Life Experience

Early Changes in Circulating T-Cell Immune Profiles in Patients with Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Data from the Phase 3, Double-Blind HELIOS Trial

Systemic Exposure of Rituximab Increased By Ibrutinib: Pharmacokinetic Results from the Helios Trial

Improvement of Quality of Response with Ibrutinib Plus Bendamustine/Rituximab Vs Placebo Plus Bendamustine/Rituximab for Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Insights into the Management of Adverse Events in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Experience from the Phase 3 HELIOS Study of Ibrutinib Combined with Bendamustine/Rituximab

Health-Related Quality of Life and Patient-Reported Outcomes in Patients Receiving Ofatumumab in Combination with Fludarabine and Cyclophosphamide (FC) Versus FC Alone in the Complement 2 Trial

Development of a High-Throughput Screening Assay with Nurse-like Cell-Based Microenviroment in Chronic Lymphoid Leukemia Cells.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only